Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

TELESTA THERAPEUTICS INC T.TST

"Telesta Therapeutics Inc is a biopharmaceutical company. The Company is engaged in the research, development, manufacturing and commercialization of human health products and technologies."


TSX:TST - Post by User

Bullboard Posts
Comment by Buck$teron Feb 27, 2011 6:04pm
238 Views
Post# 18202274

RE: RE: RE: RE: Analyst Report

RE: RE: RE: RE: Analyst ReportHey Wussy old Buddy, that looks a lot like a beautiful 'red sky at night' sunset in the gulf? I hope so, and I hope you're right about a 'few events leading to a discontinuation by a patient'.  So why would they not say "one patient". I always remember these pr's are usually well thought out to be accurate, cover their butts, and look positive. In this case we could have several negative cases, imho.

Here's a copy of the Northland Analysts disclosure.

RESEARCH DISCLOSURES
1. NCP Northland Capital Partners Inc. (“NCP”) and/or its affiliates companies do beneficially own 1% or more of any class of the issuer’s equity securities, as of the end of the month immediately preceding the date of issuance of the research report or the end of the second most recent month if the issue date is less than 10 calendar days after the end of the most recent month.
2. The authoring analyst or any associate of the authoring analyst does maintain a long or short position in any of the issuer’s securities directly or through derivatives, including options or futures positions.
3. NCP, its affiliated companies, partners, officers, directors or any authoring analyst of NCP has provided services to the issuer for remuneration during the preceding 12 months other than investment advisory or trading services.
4. NCP or any of its affiliated companies has performed investment banking services for the issuer during the 12 months preceding the date of issuance of the report.
5. A partner, director, officer, employee or agent of NCP or any of its affiliated companies is an officer, director, employee or advisor of the issuer.
6. The authoring analyst, or any associate of the authoring analyst, has viewed the material operations of the issuer. The analyst conducted meetings with management. A site visit was conducted in Belleville, Ontario.
7. The authoring analyst, or any associate of the authoring analyst, received reimbursement for travel expenses. 8. NCP makes a market in the securities of this company.
Bullboard Posts